Product-Related Results Sample Clauses

Product-Related Results. 5.2.1. GenSight’s Use and Exploitation of Product-Related Results. GenSight shall be free to exploit the Product-Related Results for any purpose at its own discretion, subject to the payment to Genethon of milestone payments and royalties. Such milestone payments and royalties shall be negotiated in good faith by the Parties in the Project Addendum or at the latest by such later date as the Parties may define in the Project Addendum, in accordance with the principles set forth hereinafter.
Sample 1Sample 2Sample 3See All (4)
AutoNDA by SimpleDocs
Product-Related Results. All Product-Related Results shall be owned by GenSight. Any and all decisions relating to the filing, prosecution, maintenance and defense of registrable intellectual property rights in respect of Product Related Results shall be at the absolute discretion of GenSight, which shall bear any and all costs associated with such activities. For the purpose above, Genethon shall assign and cause its employees and/or personnel and/or subcontractors involved in the performance of a R&D Project to assign, at no cost, all rights, titles and interests in Product-Related Results to GenSight. Genethon shall provide, and shall cause its employees and/or personnel and/or subcontractors involved in the performance of a R&D Project to provide any and all relevant information in its possession and reasonable assistance that would be useful to Genethon to file, prosecute, maintain or defend any and all intellectual property rights in respect of Product-Related Results. Genethon notably agrees to execute, and/or cause any of its employees and/or personnel and/or subcontractors involved in the performance of a R&D Project to execute, all further documents and assignments and do all necessary actions to transfer the effective ownership of Product-Related Results to GenSight or to register GenSight (or its designee) as owner of registrable rights in Process-Related Results. [**] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.
Sample 1Sample 2Sample 3See All (4)
Product-Related Results. Genethon shall not publish any Product-Related Results without the prior written consent of GenSight, such consent to be requested and dealt with during meetings of the Strategic Committee.
Sample 1Sample 2Sample 3See All (4)

Related to Product-Related Results

  • Product Recalls The Company is not aware of any pattern or series of claims against the Company or any of its subsidiaries which reasonably could be expected to result in a generalized product recall relating to products sold by the Company or any of its subsidiaries, regardless of whether such product recall is formal, informal, voluntary or involuntary.

  • Product Returns Client will have the responsibility for handling customer returns of the Products. Patheon will give Client any assistance that Client may reasonably require to handle the returns.

  • Product Recall (a) If a recall is required by applicable Law, or if Buyer or Supplier reasonably determines that a recall is advisable because the goods may create a potential safety hazard, are not in compliance with any applicable code, standard or legal requirement, or contain a defect or non-conformance with the requirements of this Order occurring or likely to occur in multiple goods, which such defects or non-conformances are substantially similar or have substantially similar causes or effects (collectively a “Serial Defect”), the parties shall promptly communicate such facts to each other. At Buyer’s request, Supplier shall promptly develop a corrective action plan satisfactory to Buyer, which shall include all actions required to recall and/or repair the goods and any actions required by applicable Law (“Corrective Action Plan”) for Buyer’s review and approval. At Buyer’s election, Xxxxx may develop the Corrective Action Plan. In no event shall Buyer and Supplier’s failure to agree on the Corrective Action Plan delay the timely notification of a potential safety hazard, non-compliance or Serial Defect to users of the goods, cause either party to be non-compliant with applicable Law or prevent Buyer from taking reasonable actions to prevent injury or damage to persons, equipment or other property. Supplier and Buyer shall cooperate with and assist each other in any corrective actions and/or filings, if applicable.

  • Results The five values obtained shall be arranged in order and the median value taken as a result of the measurement. This value shall be expressed in Newtons per centimetre of width of the tape. Annex 7 Minimum requirements for sampling by an inspector

  • Product Testing Upon request, Customer shall provide Operator a laboratory report for each Product delivery by Customer or Customer’s supplier. Operator will not be obligated to receive Contaminated Product for throughput across the Berths, nor will Operator be obligated to accept Product that fails to meet the quality specifications set forth in the arrival notice.

  • Product Quality 4.1 The following provisions shall apply to Product after Production:

  • Commercialization Reports Throughout the term of this Agreement and during the Sell-Off Period, and within thirty (30) days of December 31st of each year, Company will deliver to University written reports of Company’s and Sublicensees’ efforts and plans to develop and commercialize the innovations covered by the Licensed Rights and to make and sell Licensed Products. Company will have no obligation to prepare commercialization reports in years where (a) Company delivers to University a written Sales Report with active sales, and (b) Company has fulfilled all Performance Milestones. In relation to each of the Performance Milestones each commercialization report will include sufficient information to demonstrate achievement of those Performance Milestones and will set out timeframes and plans for achieving those Performance Milestones which have not yet been met.

  • Development Records Each Party shall maintain complete, current and accurate records of all Development activities conducted by it hereunder, and all data and other information resulting from such activities. Such records shall fully and properly reflect all work done and results achieved in the performance of the Development activities in good scientific manner [*]. Each Party shall document all non-clinical studies and clinical trials in formal written study reports according to applicable Laws and national and international guidelines (e.g., ICH, GCP, GLP, and GMP). Each Party shall have the right to review and copy such records maintained by the other Party at reasonable times and to obtain access to the original [*].

  • Field The term “

Time is Money Join Law Insider Premium to draft better contracts faster.